Literature DB >> 1613761

The clinicopathological features of three babies with osteogenesis imperfecta resulting from the substitution of glycine by valine in the pro alpha 1 (I) chain of type I procollagen.

W G Cole1, E Patterson, J Bonadio, P E Campbell, D W Fortune.   

Abstract

The features of three babies with perinatal lethal osteogenesis imperfecta (OI II) resulting from substitutions of glycine by valine in the triple helical domain of the alpha 1(I) chain of type I collagen were studied. The babies were heterozygous for this substitution at residue 1006 in case 1 (OI35), 973 in case 2 (OI59), and 256 in case 3 (OI7B). OI35 had the most severe clinical form, OI IIC, with premature rupture of membranes, severe antepartum haemorrhage, stillbirth, severe short limbed dwarfism, and extreme osteoporosis. OI59 was a better formed baby but was also born prematurely as a result of premature rupture of membranes and severe antepartum haemorrhage. She had the radiographic features of OI IIA. OI7B was born at term and also had the radiographic features of OI IIA. Pathological examination of the skeletons of OI35 and OI59 showed grossly deficient intramembranous and endochondral ossification. Trabecular bone was sparse in the long bones and vertebrae. The trabeculae contained a cartilage core and an overlying layer of woven bone or osteoid. The diaphyses lacked cortical bone. The periosteal fibroblasts of OI35 contained grossly distended rough endoplasmic reticulum consistent with the 53% reduction in collagen secretion by cultured dermal fibroblasts. The aorta, skin, and lungs were hypoplastic in OI35 and OI59. The findings in this study show that glycine substitutions by valine in Gly-X-Y triplets, from glycine 256 to glycine 1006, of the triple helical domain of alpha 1(I) chains produce the OI II phenotype. The phenotype was most severe in the baby with the most carboxy-terminal substitution.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1613761      PMCID: PMC1015850          DOI: 10.1136/jmg.29.2.112

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  22 in total

1.  Altered triple helical structure of type I procollagen in lethal perinatal osteogenesis imperfecta.

Authors:  J Bonadio; K A Holbrook; R E Gelinas; J Jacob; P H Byers
Journal:  J Biol Chem       Date:  1985-02-10       Impact factor: 5.157

2.  RNA sequence analysis of a perinatal lethal osteogenesis imperfecta mutation.

Authors:  E Patterson; E Smiley; J Bonadio
Journal:  J Biol Chem       Date:  1989-06-15       Impact factor: 5.157

3.  Collagen defects in lethal perinatal osteogenesis imperfecta.

Authors:  J F Bateman; D Chan; T Mascara; J G Rogers; W G Cole
Journal:  Biochem J       Date:  1986-12-15       Impact factor: 3.857

4.  A substitution of cysteine for glycine 748 of the alpha 1 chain produces a kink at this site in the procollagen I molecule and an altered N-proteinase cleavage site over 225 nm away.

Authors:  B E Vogel; R Doelz; K E Kadler; Y Hojima; J Engel; D J Prockop
Journal:  J Biol Chem       Date:  1988-12-15       Impact factor: 5.157

5.  A frameshift mutation results in a truncated nonfunctional carboxyl-terminal pro alpha 1(I) propeptide of type I collagen in osteogenesis imperfecta.

Authors:  J F Bateman; S R Lamande; H H Dahl; D Chan; T Mascara; W G Cole
Journal:  J Biol Chem       Date:  1989-07-05       Impact factor: 5.157

6.  Recurrence risks and prognosis in severe sporadic osteogenesis imperfecta.

Authors:  E M Thompson; I D Young; C M Hall; M E Pembrey
Journal:  J Med Genet       Date:  1987-07       Impact factor: 6.318

7.  Characterization of point mutations in the collagen COL1A1 and COL1A2 genes causing lethal perinatal osteogenesis imperfecta.

Authors:  S R Lamande; H H Dahl; W G Cole; J F Bateman
Journal:  J Biol Chem       Date:  1989-09-25       Impact factor: 5.157

8.  Perinatal lethal osteogenesis imperfecta in transgenic mice bearing an engineered mutant pro-alpha 1(I) collagen gene.

Authors:  A Stacey; J Bateman; T Choi; T Mascara; W Cole; R Jaenisch
Journal:  Nature       Date:  1988-03-10       Impact factor: 49.962

9.  Subtle structural alterations in the chains of type I procollagen produce osteogenesis imperfecta type II.

Authors:  J Bonadio; P H Byers
Journal:  Nature       Date:  1985 Jul 25-31       Impact factor: 49.962

10.  The molecular defect in an autosomal dominant form of osteogenesis imperfecta. Synthesis of type I procollagen containing cysteine in the triple-helical domain of pro-alpha 1(I) chains.

Authors:  W N de Vries; W J de Wet
Journal:  J Biol Chem       Date:  1986-07-05       Impact factor: 5.157

View more
  6 in total

1.  Arachnoid cyst and chronic subdural haematoma in a child with osteogenesis imperfecta type III resulting from the substitution of glycine 1006 by alanine in the pro alpha 2(I) chain of type I procollagen.

Authors:  W G Cole; T P Lam
Journal:  J Med Genet       Date:  1996-03       Impact factor: 6.318

2.  Disrupted growth plates and progressive deformities in osteogenesis imperfecta as a result of the substitution of glycine 585 by valine in the alpha 2 (I) chain of type I collagen.

Authors:  W G Cole; D Chan; C W Chow; J G Rogers; J F Bateman
Journal:  J Med Genet       Date:  1996-11       Impact factor: 6.318

3.  Connective tissue disease: closing on the threshold.

Authors:  A Robinson
Journal:  CMAJ       Date:  1993-10-01       Impact factor: 8.262

4.  SSCP detection of a Gly565Val substitution in the pro alpha 1(I) collagen chain resulting in osteogenesis imperfecta type II.

Authors:  K Mackay; A M Lund; M Raghunath; B Steinmann; R Dalgleish
Journal:  Hum Genet       Date:  1993-06       Impact factor: 4.132

Review 5.  Perinatal lethal osteogenesis imperfecta.

Authors:  W G Cole; R Dalgleish
Journal:  J Med Genet       Date:  1995-04       Impact factor: 6.318

Review 6.  Connective tissue and related disorders and preterm birth: clues to genes contributing to prematurity.

Authors:  E A Anum; L D Hill; A Pandya; J F Strauss
Journal:  Placenta       Date:  2009-01-18       Impact factor: 3.481

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.